Table 3.
Pharmacokinetic parameters of TETA, MAT, and DAT at 6 dose levels in EOC/PPSC patients.
| Dose level | Dose of trientine (mg/d) | TETA | MAT | DAT | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0−24 (mg × h/L) | T1/2 (hours) | Tmax (hours) | Cmax (mg/L) | AUC0−24 (mg × h/L) | T1/2 (hours) | Tmax (h) | Cmax (mg/L) | AUC0−24 (mg × h/L) | T1/2 (hours) | Tmax (hours) | Cmax (mg/L) | ||
| 1 | 300 | 8.16 (8.12) | 3.51 (2.53) | 1.50 (1.00) | 1.87 (0.86) | 29.59 (32.89) | 4.87 (0.00) | 4.00 (4.50) | 2.42 (2.96) | 7.75 (4.75) | Undetectable | 6.00 (2.00) | 0.56 (0.54) |
| 2 | 600 | 15.12 (4.12) | 2.64 (0.00) | 1.50 (1.00) | 5.07 (4.24) | 31.70 (0.98) | Undetectable | 5.00 (2.00) | 2.38 (0.04) | 5.34 (0.81) | Undetectable | 6.00 (0.00) | 0.36 (0.06) |
| 3 | 900 | 30.28 (45.49) | 1.85 (2.86) | 0.50 (0.50) | 11.54 (8.22) | 40.96 (71.21) | Undetectable | 4.00 (2.00) | 6.95 (3.81) | 4.58 (12.52) | Undetectable | 6.00 (0.00) | 0.83 (0.73) |
| 4 | 1,200 | 90.80 (56.45) | 3.93 (2.16) | 2.00 (0.50) | 14.98 (6.03) | 87.83 (99.23) | Undetectable | 4.00 (2.00) | 6.92 (7.96) | 13.43 (15.63) | Undetectable | 6.00 (0.00) | 0.94 (1.22) |
| 5 | 1,500 | 127.66 (31.35) | 3.48 (0.00) | 4.00 (3.00) | 13.08 (14.02) | 82.26 (58.94) | Undetectable | 6.00 (0.00) | 6.62 (4.71) | 16.32 (11.99) | Undetectable | 6.00 (0.00) | 1.09 (1.06) |
| 6 | 1,800 | 388.10 (0.00) | Undetectable | 6.00 (0.00) | 29.35 (0.00) | 64.47 (0.00) | Undetectable | 4.00 (0.00) | 5.53 (0.00) | 9.77 (0.00) | Undetectable | 4.00 (0.00) | 0.82 (0.00) |
Data was presented as median (interquartile range).
TETA, triethylenetetramine dihydrochloride; MAT, N1-acetyltriethylenetetramine; DAT, N1,N10-diacetyltriethylenetetramine; EOC, epithelial ovarian carcinoma; PPSC, primary peritoneal serous carcinoma.